Product Description
Omacetaxine mepesuccinate is a semisynthetic derivative of HHT with known clinical activity in relapsed or refractory CML following TKI therapy. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25301179/)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: ChemGenex
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Chronic Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20212457 | P2 |
Not yet recruiting |
Chronic Myeloid Leukemia |
None |
|
| CTR20202269 | P3 |
Not yet recruiting |
Acute Myeloid Leukemia |
None |